Klinikum Aschaffenburg-Alzenau gGmbH

The department of Haematologie und Onkologie at Klinikum Aschaffenburg-Alzenau focuses on blood‑related cancers such as acute myeloid leukemia, myelodysplastic syndrome and related high‑risk subtypes, aiming to improve survival and reduce disease progression.

• Testing targeted inhibitors for IDH1/IDH2 mutations
• Comparing FLT3 inhibitors to standard therapy
• Assessing venetoclax‑based regimens for event‑free survival
• Evaluating maintenance strategies after intensive chemotherapy

With eight investigators overseeing five active trials, the site contributes valuable data on novel treatment combinations for patients with newly diagnosed disease.

Researchers are studying patients with advanced HER2‑negative, hormone‑receptor‑positive breast cancer in the first‑line setting, exploring how molecular patterns influence response to therapies such as ribociclib.

• Analyzing spatial and temporal biomarkers of drug efficacy
• Identifying mechanisms of resistance to CDK4/6 inhibition
• Integrating molecular profiling to personalize treatment

The comprehensive approach seeks to refine therapeutic decisions and enhance outcomes for women facing this challenging disease.